Bicycle Therapeutics

Biotechnology ResearchEngland, United Kingdom201-500 Employees

Bicycle Therapeutics is a clinical-stage biotechnology company developing a novel class of medicines based on bicyclic peptide technology for cancer and other diseases. Its science centers on fully synthetic short peptides constrained with small-molecule scaffolds to form two loops, stabilizing their geometry to enable high-affinity, selective target binding. The company maintains a portfolio that includes BT8009 (formerly zelenectide pevedotin), BT5528 and BT7480, with BT7480 described as a Bicycle TICA targeting Nectin-4 and CD137, and BT5528 targeting EphA2, all in company-sponsored clinical trials. It also develops Bicycle Radio Conjugates for radiopharmaceutical use and pursues partnerships to apply its technology beyond oncology. The company is based in the United Kingdom, listing its location as Great Abington, England, and has historically cited Cambridge, UK as its headquarters with leadership presence in Lexington, MA; it has 201-500 employees and is listed on NASDAQ under the ticker BCYC.

Sign up for free to view info

Email Format Employee directory